In particular, the PRMT5 inhibitor EZP015556 was shown to target pancreatic tumors negative for MTAP (a gene commonly lost in pancreatic cancer), as well as a subset of MTAP-positive tumors [34]. This evidence concerns the gene PRMT5 and pancreatic neoplasm.